Loading
A phase 2 trial of Alisertib in HR-positive / HER2-negative breast cancer, run by Puma Biotechnology, Inc., now recruiting.
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06369285 by Puma Biotechnology, Inc., with 225 participants planned, started 2024-11-19 and due to reach its primary completion in 2027-12-30. Interventions recorded: Alisertib and Endocrine therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Alisertib, Puma Biotechnology and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/